Est. 2019 · Pharmaceutical research, development, technology & contract services · Hyderabad, India sales@dgxpcompliancelab.com Careers

Capability

Product & Formulation Development

From prototype to a robust, scalable formulation: dosage-form design, optimisation and the process knowledge that makes a product manufacturable.

Oral solid dosage train showing powder processing, granulation and compression areas
Formulation scientist weighing material with an electronic record on a tablet

What we do

Formulation work succeeds when formulation, analytical and process decisions are made together. We structure development around critical quality attributes and use designed experiments to understand which variables matter before scale-up.

Dosage forms listed below are areas we can discuss and scope. Specific capability for any product category is confirmed only after technical assessment and partner availability.

Where it fits in the pharmaceutical lifecycle

Typical activities

Each activity shows who performs it. We do not claim facilities we do not own.

DGXP-led Led by the DGXPComplianceLab team Partner-coordinated Performed by a qualified partner, coordinated by us

  • Tablets

    Partner-coordinated

    Direct compression, wet and dry granulation, coating; hardness, friability and dissolution targets.

  • Capsules

    Partner-coordinated

    Powder and pellet filling, fill-weight uniformity and shell selection.

  • Oral liquids

    Partner-coordinated

    Solutions and suspensions: preservative efficacy, taste masking, viscosity and redispersibility.

  • Topical formulations

    Partner-coordinated

    Creams, gels and ointments: rheology, release testing and container compatibility.

  • Sterile products

    Partner-coordinated

    Parenteral formulation considerations, filtration, terminal sterilisation versus aseptic route.

  • Novel formulations

    Partner-coordinated

    Modified release and enabling technologies, scoped case by case.

  • Generic product development

    DGXP-led

    Reference product deformulation, Q1/Q2 assessment and comparative dissolution.

  • Product optimisation

    DGXP-led

    Root-cause analysis of variability and targeted reformulation.

  • Process optimisation

    DGXP-led

    Parameter studies, yield improvement and robustness evaluation.

Typical project types

Formulation optimisation

Reduce variability in dissolution or content uniformity through a structured DoE.

Process scale-up

Move from laboratory to pilot and exhibit scale with a documented rationale.

Analytical method development

Stability-indicating methods ready for validation at the receiving laboratory.

Technology transfer

A transfer package the manufacturing site can execute without re-discovery.

Formulation development path

  1. 1Target product profile
  2. 2Pre-formulation
  3. 3Prototype trials
  4. 4Optimisation (DoE)
  5. 5Analytical support
  6. 6Scale-up batch
  7. 7Development report
  8. 8Transfer

Technologies and processes

  • Fluid bed processing
  • High-shear granulation
  • Roller compaction
  • Tablet compression & coating
  • Encapsulation
  • Design of Experiments
  • Comparative dissolution (f2)

Our project execution model

Every engagement follows the same eight steps, scaled to the size and risk of the project.

  1. 01

    Understand

    Understand business and technical requirements.

  2. 02

    Assess

    Assess scientific, technical, regulatory and operational requirements.

  3. 03

    Design

    Design the appropriate solution.

  4. 04

    Identify

    Identify appropriate internal and external capabilities and partners.

  5. 05

    Execute

    Coordinate and execute the project.

  6. 06

    Verify

    Test, verify, qualify or validate where applicable.

  7. 07

    Document

    Create technical, quality and regulatory documentation.

  8. 08

    Improve

    Monitor, optimise and continuously improve.

Frequently asked questions

Which dosage forms can you support?

We scope each request against partner capability. Oral solids are the most common starting point; other forms are assessed individually.

Do you use Quality by Design?

Yes. Development plans are built around critical quality attributes, risk assessment and designed experiments, in line with ICH Q8–Q10 principles.

Who owns the development data?

Ownership and confidentiality are agreed in the project contract before work begins.

Discuss a formulation development requirement

Share the product, stage and timeline. Capability is confirmed after technical assessment and partner availability.